The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 1×
“RELA–p50 dimers are subsequently released and translocate to the nucleus where they activate the transcription of various target gene”
Self-citationNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Self-citationDu, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Self-citationThe Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
The two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
Self-citationIKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Self-citationNF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., & Vaux, D. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00009-x · Cited by 2,372
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“The crucial role played by the inflammatory microenvironment in the natural history and progression of most cancers offers new opportunities to therapeutic intervention based on targeting the inflammatory components of the tumour rather than the malignant cell, which is quick to mutate and acquire drug resistanc”
BackgroundSelf-citationSmoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Signal transduction by tumor necrosis factor and its relatives
Baud, V., & Karin, M. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02064-5 · Cited by 1,655
Self-citationHideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Self-citationKyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1
Malinin, N. L., Boldin, M. P., Kovalenko, A. V., & Wallach, D. (1997) · Nature · doi:10.1038/385540a0 · Cited by 1,280
Rothe, M., Pan, M.-G., Henzel, W. J., Ayres, T. M., & V. Goeddel, D. (1995) · Cell · doi:10.1016/0092-8674(95)90149-3 · Cited by 1,253
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218 · cited 1×
“Within this complex, cIAP1 and cIAP2 are directly responsible for the degradative K48-linked polyubiquitylation of NI”
BackgroundCharacterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065
Rothe, M., Wong, S. C., Henzel, W. J., & Goeddel, D. V. (1994) · Cell · doi:10.1016/0092-8674(94)90532-0 · Cited by 1,054
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis
Vince, J. E., Wong, W. W.-L., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.037 · Cited by 1,053
Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., & Ashwell, J. D. (2000) · Science · doi:10.1126/science.288.5467.874 · Cited by 988
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983
Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways
Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z.-W., Karin, M., Ware, C. F., & Green, D. R. (2002) · Immunity · doi:10.1016/s1074-7613(02)00423-5 · Cited by 922
Self-citationNF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J.-L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 878
NF-κB-Inducing Kinase Regulates the Processing of NF-κB2 p100
Xiao, G., Harhaj, E. W., & Sun, S.-C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00187-3 · Cited by 834
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells
Claudio, E., Brown, K., Park, S., Wang, H., & Siebenlist, U. (2002) · Nature Immunology · doi:10.1038/ni842 · Cited by 693
Bharti, A. C., Donato, N., Singh, S., & Aggarwal, B. B. (2003) · Blood · doi:10.1182/blood-2002-05-1320 · Cited by 685
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X., & Harran, P. G. (2004) · Science · doi:10.1126/science.1098231 · Cited by 656
IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation
Lawrence, T., Bebien, M., Liu, G. Y., Nizet, V., & Karin, M. (2005) · Nature · doi:10.1038/nature03491 · Cited by 626
Self-citationHerceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Greten, F. R., Arkan, M. C., Bollrath, J., Hsu, L.-C., Goode, J., Miething, C., Göktuna, S. I., Neuenhahn, M., Fierer, J., Paxian, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.009 · Cited by 616
Self-citationIAPs, RINGs and ubiquitylation
Vaux, D. L., & Silke, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1621 · Cited by 610
Vallabhapurapu, S., Matsuzawa, A., Zhang, W., Tseng, P.-H., Keats, J. J., Wang, H., Vignali, D. A. A., Bergsagel, P. L., & Karin, M. (2008) · Nature Immunology · doi:10.1038/ni.1678 · Cited by 608
Self-citationThe inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Liao, G., Zhang, M., Harhaj, E. W., & Sun, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403286200 · Cited by 465
TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2
Li, X., Yang, Y., & Ashwell, J. D. (2002) · Nature · doi:10.1038/416345a · Cited by 452
Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κb-inducing kinase
Shinkura, R., Kitada, K., Matsuda, F., Tashiro, K., Ikuta, K., Suzuki, M., Kogishi, K., Serikawa, T., & Honjo, T. (1999) · Nature Genetics · doi:10.1038/8780 · Cited by 450
Lucito, R., Healy, J., Alexander, J., Reiner, A., Esposito, D., Chi, M., Rodgers, L., Brady, A., Sebat, J., Troge, J., et al. (2003) · Genome Research · doi:10.1101/gr.1349003 · Cited by 441
CD40 regulates the processing of NF-kappaB2 p100 to p52
Coope, H. J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf542 · Cited by 440
Shu, H.-B., Takeuchi, M., & Goeddel, D. V. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13973 · Cited by 423
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity
Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M.-J., Pedersen, I. M., Kitada, S., Scott, F. L., Bailly-Maitre, B., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00332-5 · Cited by 411
Defective Lymphotoxin-β Receptor-Induced NF-κB Transcriptional Activity in NIK-Deficient Mice
Yin, L., Wu, L., Wesche, H., Arthur, C. D., White, J. M., Goeddel, D. V., & Schreiber, R. D. (2001) · Science · doi:10.1126/science.1058453 · Cited by 409
Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
Jost, P. J., & Ruland, J. (2007) · Blood · doi:10.1182/blood-2006-07-025809 · Cited by 408
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Pomerantz, J. L., & Baltimore, D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00697-4 · Cited by 393
From signatures to models: understanding cancer using microarrays
Segal, E., Friedman, N., Kaminski, N., Regev, A., & Koller, D. (2005) · Nature Genetics · doi:10.1038/ng1561 · Cited by 381
Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.11.4079 · Cited by 367
Sasaki, Y., Casola, S., Kutok, J. L., Rajewsky, K., & Schmidt-Supprian, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2245 · Cited by 365
Dejardin, E. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.007 · Cited by 344
Shulga-Morskaya, S., Dobles, M., Walsh, M. E., Ng, L. G., MacKay, F., Rao, S. P., Kalled, S. L., & Scott, M. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2331 · Cited by 258
Gardam, S., Sierro, F., Basten, A., Mackay, F., & Brink, R. (2008) · Immunity · doi:10.1016/j.immuni.2008.01.009 · Cited by 248
STI571 (Gleevec™) as a paradigm for cancer therapy
Druker, B. J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02305-5 · Cited by 245
Ramakrishnan, P., Wang, W., & Wallach, D. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.009 · Cited by 232
Essential Cytoplasmic Translocation of a Cytokine Receptor–Assembled Signaling Complex
Matsuzawa, A., Tseng, P.-H., Vallabhapurapu, S., Luo, J.-L., Zhang, W., Wang, H., Vignali, D. A. A., Gallagher, E., & Karin, M. (2008) · Science · doi:10.1126/science.1157340 · Cited by 217
Self-citationInhibitor of Apoptosis Protein cIAP2 Is Essential for Lipopolysaccharide-Induced Macrophage Survival
Conte, D., Holcik, M., Lefebvre, C. A., LaCasse, E., Picketts, D. J., Wright, K. E., & Korneluk, R. G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.2.699-708.2006 · Cited by 191
Posttranscriptional Downregulation of c-IAP2 by the Ubiquitin Protein Ligase c-IAP1 In Vivo
Conze, D. B., Albert, L., Ferrick, D. A., Goeddel, D. V., Yeh, W.-C., Mak, T., & Ashwell, J. D. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3348-3356.2005 · Cited by 189
Landowski, T. H., Olashaw, N. E., Agrawal, D., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206315 · Cited by 186
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 172
Rescue of TRAF3-null mice by p100 NF-κB deficiency
He, J. Q., Zarnegar, B., Oganesyan, G., Saha, S. K., Yamazaki, S., Doyle, S. E., Dempsey, P. W., & Cheng, G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061166 · Cited by 165
Yamada, T., Mitani, T., Yorita, K., Uchida, D., Matsushima, A., Iwamasa, K., Fujita, S., & Matsumoto, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.804 · Cited by 162
Derudder, E., Dejardin, E., Pritchard, L. L., Green, D. R., Körner, M., & Baud, V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300106200 · Cited by 160
Self-citationNi, H., Ergin, M., Huang, Q., Qin, J., Amin, H. M., Martinez, R. L., Saeed, S., Barton, K., & Alkan, S. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03102.x · Cited by 159
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Chauhan, D., Neri, P. E., Velankar, M., Podar, K., Hideshima, T., Fulciniti, M., Tassone, P., Raje, N. S., Mitsiades, C. S., Mitsiades, N., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015149 · Cited by 151
MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo
Hideshima, T., Neri, P. E., Tassone, P., Yasui, H., Ishitsuka, K., Raje, N. S., Chauhan, D., Podar, K., Mitsiades, C. S., Dang, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2501 · Cited by 136
Dying for NF-κB? Control of cell death by transcriptional regulation of the apoptotic machinery
Burstein, E., & Duckett, C. S. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.005 · Cited by 128
The Anti-Death Machinery in IKK/NF-κB Signaling
Luo, J., Kamata, H., & Karin, M. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-8217-6 · Cited by 119
Self-citationSpecificity of TRAF3 in Its Negative Regulation of the Noncanonical NF-κB Pathway
He, J. Q., Saha, S. K., Kang, J. R., Zarnegar, B. J., & Cheng, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m610271200 · Cited by 117
Orellana, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01154-9 · Cited by 115
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
Hussein, M. A., Saleh, M. N., Ravandi, F., Mason, J. R., Rifkin, R. M., & Ellison, R. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04941.x · Cited by 114
Sasaki, Y., Calado, D. P., Derudder, E., Zhang, B., Shimizu, Y., Mackay, F., Nishikawa, S., Rajewsky, K., & Schmidt‐Supprian, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805186105 · Cited by 113
Nuclear factor B as a target for new drug development in myeloid malignancies
Cilloni, D., Martinelli, G., Messa, F., Baccarani, M., & Saglio, G. N. (2007) · Haematologica · doi:10.3324/haematol.11199 · Cited by 103
Dai, Y., Pei, X., Rahmani, M., Conrad, D. H., Dent, P., & Grant, S. (2003) · Blood · doi:10.1182/blood-2003-09-3037 · Cited by 100
Niesvizky, R., Richardson, P. G. G., Rajkumar, S. V., Coleman, M., Rosiñol, L., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07303.x · Cited by 98
The malignant clone and the bone-marrow environment
Podar, K., Richardson, P. G. G., Hideshima, T., Chauhan, D., & Anderson, K. C. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.002 · Cited by 98
Cytokines and signal transduction
Hideshima, T., Podar, K., Chauhan, D., & Anderson, K. C. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.003 · Cited by 97
Broek, I. V., Asosingh, K., Allegaert, V., Leleu, X. P., Facon, T. T. F., Vanderkerken, K., Camp, B. V., & Riet, I. V. (2004) · Leukemia · doi:10.1038/sj.leu.2403331 · Cited by 81
Growth Inhibition of Multiple Myeloma Cells by a Novel IκB Kinase Inhibitor
Sanda, T., Iida, S., Ogura, H., Asamitsu, K., Murata, T., Bacon, K. B., Ueda, R., & Okamoto, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1936 · Cited by 74
Molecular diagnosis of lymphoid malignancies by gene expression profiling
Davis, R. E., & Staudt, L. M. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00011 · Cited by 67
Disease-specific genomic analysis: identifying the signature of pathologic biology
Nicolau, M. M., Tibshirani, R. J., Børresen‐Dale, A., & Jeffrey, S. S. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm033 · Cited by 61
Targeting NF‐κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth
Jourdan, M., Moreaux, J., Vos, J. D., Hose, D., Mahtouk, K., Abouladzé, M., Robert, N., Baudard, M., Reme, T. X., Romanelli, A., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06629.x · Cited by 56
Deregulated NF-κB activity in haematological malignancies
Keutgens, A., Robert, I., Viatour, P., & Chariot, A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.011 · Cited by 54
Feng, R., Anderson, G., Xiao, G., Elliott, G. T., Leoni, L. M., Mapara, M. Y., Roodman, G. D., & Lentzsch, S. (2006) · Blood · doi:10.1182/blood-2006-07-027458 · Cited by 46
Hecht, M., von Metzler, I., Sack, K., Kaiser, M., & Sezer, O. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.10.021 · Cited by 38
State of the art therapy in multiple myeloma and future perspectives
Denz, U., Haas, P. S., Wäsch, R., Einsele, H., & Engelhardt, M. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.040 · Cited by 34
Chanock, S. J., Burdett, L. A., Yeager, M., Llaca, V., Langerød, A., Presswala, S., Kaaresen, R., Strausberg, R. L., Gerhard, D. S., Kristensen, V. N., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1637 · Cited by 32
Yosef, N., Yakhini, Z., Tsalenko, A., Kristensen, V. N., Børresen‐Dale, A., Ruppin, E., & Sharan, R. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl298 · Cited by 25
Wang, H., HAN, H., Mousses, S., & VonHoff, D. D. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.013 · Cited by 25
Activation of the Ras-related GTPase Rap1 by thymocyte TCR engagement and during selection
(2000) · Pure Amsterdam UMC · doi:10.1002/1521-4141(200010)30:10 · Cited by 3
Research works printed but not linked: 2
- Engelhardt, M. & Mertelsmann, R. 160 years of multiple myeloma: progress and challenges. Eur. J. Cancer 42, 1507–1509 (2006). · doi:10.1016/j.ejca.2006.05.003
- Karrer, U., Althage, A., Odermatt, B., Hengartner, H. & Zinkernagel, R. M. Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect of secondary lymphoid organs and functional B cell defect. Eur. J. Immunol. 30, 2799–2807 (2000). · doi:10.1002/1521-4141(200010)30:10<2799::aid-immu2799>3.0.co;2-2
Cited by
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382
Metadata
- Authors
- Baud, V., & Karin, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-01
- Volume
- 8
- Issue
- 1
- Pages
- 33-40
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074688366
- Cited by
- 1,061
- References
- 103
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.